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Background: Permanent cardiac pacemakers (PCM) are accepted as the most effective treatment for
symptomatic bradyarrhythmias. Serum uric acid (UA) levels are associated with various inﬂammatory
markers, oxidative stress, and endothelial dysfunction. This study aimed to investigate the association
between serum UA and ventricular pacing threshold (VPT) levels in patients who underwent permanent
pacemaker implantation.
Materials and methods: We retrospectively analyzed a total of 198 patients who underwent PCM implan-
tation for indications such as symptomatic bradycardia without a reversible etiology and high-degree
and complete atrioventricular block.
Results: VPT values were found to correlate with serum UA levels (r=0.591, p<0.001), high sensitivity
C-reactive protein (hs-CRP) levels (r=0.505, p<0.001), and ventricular impedance (r=0.220, p=0.016).
The serum UA levels and hs-CRP levels were also correlated (r=0.691, p<0.001). To identify independent
risk factors for VPT values, a multivariate linear regression model was conducted, and serum UA levels
(ˇ =0.361, p=0.001), hs-CRP levels (ˇ =0.277, p=0.012), and impedance values (ˇ =0.207, p=0.011)were
found to be independent risk factors for VPT.
Conclusion: In thepresent study, VPTvalues at the timeof implantation andat the30thdaywere increased
in patients with high serum UA levels. To further extend the life of pacemakers, as well as other factors
that affect threshold values, serum UA levels should be noted.
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Permanent cardiac pacemakers (PCM) are accepted as the most
ffective treatment for symptomatic bradyarrhythmias and play
n important role in interventional cardiology practices world-
ide. During PCM implantation, three essential pacing parameters
hould be tested: sensing, lead impedance, and pacing thresh-
ld. Pacing threshold [measured in volts (V)] and pulse width [in
illiseconds (ms)] is deﬁned as the minimum amount of energy
eeded to capture the myocardial tissue electrically. Unnecessary
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ras¸tırma Hastanesi, Hastane Cad. Merkez/Adiyaman 02030, Turkey.
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high pacing output adversely shortens the battery life of the PCM
and is inﬂuenced by physiologic and pharmacologic factors. Several
factors such as myocardial infarction, hyperkalemia, severe acido-
sis or alkalosis, or drugs such as bretylium, ﬂecainide, propafenone,
sotalol, and others [1–3] may increase pacing thresholds.
Uric acid (UA) is the end product of purine metabolism cat-
alyzed by xanthine oxidase from hypoxanthine or xanthine. The
serum UA level has been shown to be an important and inde-
pendent risk factor in the development of cardiovascular disease
[4–6]. Additionally, serum UA levels are associated with various
inﬂammatory markers, oxidative stress, and endothelial dysfunc-
tion [7–10]. However, to our knowledge, no study has investigated
the effects of serum UA levels on pacing thresholds. This study
aimed to investigate the association between serum UA and ven-
tricular pacing threshold levels in patients who underwent PCM
implantation.
vier Ltd. All rights reserved.
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3.53±0.72mg/dL, p<0.001, respectively). But there are no dif-
ferences with regard to median decreases in the serum UA
(0.19±0.33mg/dL vs. 0.23±0.20mg/dL, p=0.382) and hs-CRP lev-
els between the groups 0.12±0.15mg/dL vs. 0.17±0.32mg/dL,
Table 1
Baseline clinical and laboratory characteristics of the study population.
Parameters Group 1
N=83
Group 2
N=38
p-Value
Age (years) 68.71±11.96 69.87±15.35 0.682
Female (n, %) 41 (49.4) 16 (42.1) 0.456
DM (n, %) 20 (24.1) 8 (21.1) 0.713
HT (n, %) 41 (49.4) 22 (57.9) 0.385
Smoking (n, %) 11 (13.3) 8 (21.1) 0.274
Hyperlipidemia (n, %) 17 (20.5) 10 (26.3) 0.474
History of CAD (n, %) 33 (39.8) 16 (42.1) 0.807
Ejection fraction (%) 55.96±4.61 55.67±4.44 0.769
Glucose (mg/dL) 103.18±37.03 106.15±41.68 0.713
Creatinine (mg/dL) .91± .21 .95± .27 0.391
Na (mEq/L) 137.04±3.60 137.56±3.57 0.460
Ca (mEq/L) 8.67± .63 8.57± .59 0.388
K (mEq/L) 4.18± .54 4.19± .55 0.934
AST (mg/dL) 19.88±12.80 18.76±13.51 0.666
ALT (mg/dL) 18.17±14.93 17.45±15.76 0.809
hs-CRP (mg/dL) 2.52±0.25 3.69±0.75 <0.001
Uric acid (mg/dL) 5.06±1.05 8.44±1.19 <0.001
Medications
Acetylsalicylic acid (n, %) 31 (37.3) 16 (42.1) 0.618
Statin (n, %) 10 (12.0) 5 (13.2) 0.863
ACE inhibitor (n, %) 14 (16.9) 11 (28.9) 0.128
ARB (n, %) 24 (28.9) 15 (39.5) 0.249
NSAID use (n, %) 28 (33.7) 13 (34.2) 0.95908 M. Ballı et al. / Journal of
ethods
tudy design and population
We retrospectively analyzed a total of 198 patients who under-
ent PCM implantation at our institution between 2010 and
013 with the indications including symptomatic bradycardia
ithout a reversible etiology and high-degree and complete atri-
ventricular block. In the ﬁrst stage, without knowledge of the
atients’ pacing parameters, two different cardiologists collected
emographic/clinical data, echocardiographic data, and bio-
hemical/hematological laboratory results from digital/non-digital
ecords. Patients were excluded according to the following crite-
ia: left ventricular systolic dysfunction (left ventricular ejection
raction<45%), acute coronary syndrome, history of myocardial
nfarction, serumcreatinine >1.5mg/dL, hypo- orhyperthyroidism,
ight ventricular leads located in an area other than apex, active
xation mechanism, epicardial leads, and patients taking antiar-
hythmic and UA lowering drugs. Such patients were excluded
ecause they may have other reasons than UA to have higher
entricular pacing thresholds (e.g. ﬁbrosis, scar). In the last stage,
different experienced interventional cardiologist evaluated the
emaining 121patients. The patientswere divided into twogroups:
ormal serum UA level (<7mg/dL as Group 1) or higher serum UA
evel (≥7mg/dL as Group 2) according to the upper-normal limit of
mg/dL.
Patient charts were reviewed for demographic data such as
iabetes, hypertension, hyperlipidemia, smoking, coronary artery
isease, and drug usage for the last three-month period. Left
entricular ejection fraction was measured using echocardiog-
aphy (General Electric, Vivid S5, Wauwatosa, WI, USA) after
dmission.
Blood samples were obtained by venipuncture on the same day
f the procedure after 12h fasting and drawn into standardized
ubes that were delivered to the laboratory within a few minutes.
erum UA levels were measured in a clinical chemistry autoana-
yzer (Modular P, Roche Diagnostics, Basel, Switzerland) using an
nzymatic colorimetricmethod, high-sensitivity C-reactive protein
hs-CRP) concentration was determined by an immunoturbidimet-
ic test (Roche Diagnostics), and other blood parameters were
easured using standard methods.
acemaker implantation and measurements
We implanted isoFlex S model (St. Jude Medical, St. Paul,
N, USA) or CapSure SP novus (Medtronic, Minneapolis, MN,
SA) bipolar ventricular leads in all patients. All ventricular
eads were steroid-eluting with a passive ﬁxation mechanism
nd were implanted into the right ventricular apex via a per-
utaneous subclavian vein puncture. The lead impedance and
-wave amplitude were assessed at the time of implantation.
acing threshold was deﬁned as the minimum voltage that
ould produce ﬁve consecutive stimuli and was measured at a
ulse duration of 0.5ms. The pacing threshold of all implanted
entricular leads was under 1.0V. After reaching a satisfactory
easurement, the leads were implanted in the optimal position,
nd then the pacemaker generators were placed in the sub-
ectoral area. All patients were reevaluated 30 days later after
mplantation.
thical considerationsThe study was approved by the local Ethics Committee on the
asis of strict maintenance of participant anonymity. Individual
nformed consent was obtained from all subjects.logy 64 (2014) 207–210
Statistical analysis
Continuous data are presented as means± SD. Differences in
continuous variables between groups were determined by t-
test. The Kolmogorov–Smirnov test was used to evaluate the
distribution of continuous variables. Categorical variables were
summarized as percentages and compared with the Chi-square
test. Correlation analysis was performed using Pearson’s test. The
variables including age, sex, diabetes mellitus, history of cardio-
vascular disease, serum UA, ventricular impedance, and ejection
fraction were identiﬁed as potential risk markers and included in
the full multivariate regression model as covariates. Results were
considered signiﬁcant when the p-value was <0.05. All statistical
analyses were performed with the SPSS version 20 (Cary, NC, USA).
Results
Demographic and clinical characteristics of the study groups
are shown in Table 1. The study population consisted of 121
patients [mean age, 69.07±13.06 years; 57 females (47.1%)], of
whom 83 were in Group 1, with normal UA levels [(mean age,
68.71±11.96 years; 41 females (49.4%)] and 38 were in Group 2,
with high UA levels [mean age, 69.86±15.35 years; 16 females
(42.1%)]. The baseline demographic and clinical characteristics of
the two groups were similar. Laboratory measurements, left ven-
tricular ejection fraction, and medications were also similar in
both groups, except that the mean serum UA and hs-CRP levels
were higher in Group 2 (5.06±1.05mg/dL vs. 8.44±1.19mg/dL,
2.52±0.25mg/dL vs. 3.69±0.75mg/dL, p<0.001, respectively) at
the time of implantation, as expected. Serum UA and hs-CRP
levels of the groups 30 days later were also higher in Group
2 (4.86±1.00mg/dL vs. 8.20±1.29mg/dL, 2.40±0.28mg/dL vs.DM, diabetes mellitus; HT, hypertension; CAD, coronary artery disease; Na, sodium;
Ca, calcium; K, potassium; AST, aspartate transaminase; ALT, alanine transaminase;
hs-CRP, high-sensitivity C-reactive protein; ACE, angiotensin-converting enzyme;
ARB, angiotensin receptor blocker; NSAID, non-steroidal anti-inﬂammatory drug.
p-Value of <0.05 was considered signiﬁcant.
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Table 2
Serum uric acid and hs-CRP levels of the groups at the time of implantation and 30
days later.
Group 1
(N=83)
Group 2
(N=38)
p-Value
Uric acid, at implantation (mg/dL) 5.06 ± 1.05 8.44 ± 1.19 <0.001
Uric acid, at 30th day (mg/dL) 4.86 ± 1.00 8.20 ± 1.29 <0.001
 Uric acid (mg/dL) 0.19 ± 0.33 0.23 ± 0.20 0.382
hs-CRP, at implantation (mg/dL) 2.52 ± 0.25 3.69 ± 0.75 <0.001
hs-CRP, at 30th day (mg/dL) 2.40 ± 0.28 3.53 ± 0.72 <0.001
 hs-CRP (mg/dL) 0.12 ± 0.15 0.17 ± 0.32 0.376
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s-CRP, high-sensitivity C-reactive protien; , median decreases. p-Value of <0.05
as considered signiﬁcant.
= 0.376) (Table 2). Pacing parameters of ventricular leads at the
ime of implantation are presented in Table 3. Mean R-wave ampli-
udes and impedance values were similar between the two groups,
xcept that the mean threshold values were signiﬁcantly higher
n the high UA group (0.39±0.18V vs. 0.63±0.18V, p<0.001). In
ddition, implanted pacemaker types and ventricular lead models
id not differ between the groups. Any atrial arrhythmia episode
as also observed during the follow-up period.
Comparison of the two groups with respect to ventricular
hreshold values at the implantation and at day 30 is presented
n Table 4. Signiﬁcant differences were found between the groups
ith respect to the ventricular threshold values at the time of
mplantation (0.39±0.18V vs. 0.63±0.18V, p<0.001) and at 30th
ay (0.30±0.09V vs. 0.62±0.22V, p<0.001). Median threshold
ecreases were found to be higher in Group 1 (0.09±0.14V vs.
.05±0.09V, p=0.054), as expected.
Among the above-mentioned parameters, ventricular thresh-
ld values were found to correlate with serum UA levels (r=0.591,
< 0.001) (Fig. 1), hs-CRP levels (r=0.505, p<0.001), and ventric-
lar impedance (r=0.220, p=0.016). The serum UA levels and
s-CRP levels were also correlated (r=0.691, p<0.001) (Fig. 2).
o identify independent risk factors for ventricular threshold val-
es, a multivariate linear regression model was conducted that
ncluded the following covariates: age, sex, diabetes mellitus,
able 3
omparison of pacing parameters of ventricular leads.
Parameters Group 1
N=83
Group 2
N=38
p-Value
R wave (mV) 12.52±5.84 12.43±5.68 0.940
Impedance () 773.18±141.87 780.89±151.84 0.786
Threshold (V) 0.39±0.18 0.63±0.18 <0.001
Pacemaker type
VVI-R 29 (34.9) 18 (47.4) 0.193
VDD 11(13.3) 5 (13.2) 0.989
DDD-R 43 (51.8) 15 (39.5) 0.208
aAtrial threshold (V) 0.60±0.16 0.75±0.18 0.004
Lead model 0.520
St. Jude 32 (38.6) 17 (44.7)
Medtronic 51 (61.4) 21 (55.3)
a Atrial threshold values of the DDD-R type pacemakers are shown.
-Value of <0.05 was considered signiﬁcant.
able 4
entricular threshold values of the groups at the time of implantation and 30 days
ater.
Group 1
(N=83)
Group 2
(N=38)
p-Value
Threshold, at implantation (V) 0.39 ± 0.18 0.63 ± 0.18 <0.001
Threshold, at 30th day (V) 0.30 ± 0.09 0.62 ± 0.22 <0.001
 Threshold (V) 0.09 ± 0.14 0.05 ± 0.09 0.054
, median threshold decreases. p-Value of <0.05 was considered signiﬁcant.Fig. 1. Correlation between ventricular threshold values and serum uric acid levels.
historyof cardiovasculardisease, serumUA,ventricular impedance,
and ejection fraction. Serum UA levels (ˇ =0.361, p=0.001),
hs-CRP levels (ˇ =0.277, p=0.012), and impedance values
(ˇ =0.207, p=0.011) were found to be independent risk factors for
ventricular threshold.
Discussion
To our knowledge, this is the ﬁrst study of the relationship
betweenserumUAlevels andventricularpacing thresholdvalues in
patientswhounderwent PCM implantation.We found that patients
withhigh serumUA levels at the timeof implantationhad increased
ventricular pacing threshold values compared to those with low
serumUA levels. On the30thday,median thresholddecreaseswere
found to be higher in patients with low serum UA levels. Addi-
tionally, serum UA levels and impedance values were independent
predictors for ventricular pacing thresholds.
Many factors may alter the pacing threshold. Myocardial
ischemia and infarction, hypothermia, hypothyroidism, hyper-
kalemia, acid–base imbalance, antiarrhythmic drugs, severe
Fig. 2. Correlation between serum high-sensitivity C-reactive protein (hs-CRP) and
uric acid levels.
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ypoxia, overt hyperglycemia, and hypoglycemia are known to
ncrease the pacing threshold, whereas catecholamines, stress,
nxiety, anticholinergic drugs, glucocorticoids, hyperthyroidism,
nd hypermetabolic state are known to decrease the pacing thresh-
ld [1–3]. In the current study, serum UA levels were shown to
ncrease the pacing threshold. Because patients with these addi-
ional factors were excluded from the study, we believe that
hanges in ventricular threshold values may only be associated
ith serum UA levels.
UA is the ﬁnal oxidation product of purine catabolism. It was
roposed recently that the antioxidant properties of UA might
e protective against oxidative stress and oxidative cell injury.
owever, in epidemiological and clinical studies, hyperuricemia
as been suggested to be a risk factor for cardiovascular dis-
ase, in which enhanced oxidative stress plays an important
athophysiological role [11,12]. Serum UA was found to have
deleterious impact on the cardiovascular system, including
ediation of the immune response upon cell injury, increas-
ng endotoxin-stimulated tumor necrosis factor-alpha production
nd hence, proinﬂammatory immune activation. Under in vitro
onditions, UA has been demonstrated to promote low-density
ipoproteinoxidation, platelet activationandadhesion [13–16], and
o stimulate proliferation, angiotensin II production, and oxida-
ive stress in vascular smooth muscle cells through the tissue
enin–angiotensin system [17]. Yu et al. suggested a novel mech-
nism of UA-induced endothelial dysfunction in that UA-induced
ging and death of human endothelial cells are mediated by the
ocal activation of oxidative stress and the renin–angiotensin sys-
em [18]. Growing evidence also shows the relationship between
mpaired oxidative metabolism (due to the increased release of
xygen free radicals) and cardiac hypertrophy, myocardial ﬁbro-
is, and remodeling [19,20]. Changes in the structure of myocardial
issue (suchasﬁbrosis) lead to an increased thresholdofmyocardial
xcitability, which affects myocardial electrophysiological proper-
ies and also increases the incidence of arrhythmic events [21].
lthough the exact mechanism by which UA increases the pac-
ng threshold is unclear, we believe that high serum UA levels
ight adversely affect the pacing threshold by causing subclinical
ndomyocardial changes such as inﬂammation and ﬁbrosis. More-
ver, correlation of the serum UA levels with the serum hs-CRP
evels in these patients seems to support this thesis. The present
tudy also suggested that a serum UA level greater than 7mg/dL
ight indicate increased oxidative stress and increased pro-
xidant rather than indicating that the supranormal levels are an
ntioxidant.
tudy limitations
This was a case–control study that included a relatively small
umber of patients. Larger prospective studies are needed to
how the relationship between serum UA levels and ventricu-
ar pacing threshold. As all data were based on a short-term
ollow-up, the accurate association of serum UA levels and ven-
ricular pacing threshold needs to be supported with long-term
ollow-up.
onclusion
In the present study, ventricular threshold values at the time
f implantation and the 30th day were increased in patients with
igh serum UA levels. Low thresholds are preferable to maximize
he battery life of the pacemakers. To further extend the life of
acemakers, as well as other factors that affect threshold values,
erum UA levels should be noted. However, this hypothesis should
e conﬁrmed with larger and long-term prospective studies.
[logy 64 (2014) 207–210
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